Antiplatelet therapy may decrease HCC incidence and improve post-treatment outcomesOctober 24, 2022Hepatocellular Carcinoma
Hepatectomy recommended for select patients with multiple HCCOctober 24, 2022Hepatocellular Carcinoma
Ramucirumab effective in patients with advanced HCC and AFP ≥400 ng/mL after non-sorafenib therapiesOctober 24, 2022Hepatocellular Carcinoma
Unresectable HCC: Atezolizumab plus bevacizumab proves its worth in the clinicOctober 24, 2022Hepatocellular Carcinoma
TARE vs TACE prolongs time to progression in HCC but not overall survivalSeptember 19, 2022Hepatocellular Carcinoma
Baseline DCP levels and NLR predict survival in patients receiving atezolizumab+bevacizumab for advanced HCCSeptember 19, 2022Hepatocellular Carcinoma
First-line lenvatinib+toripalimab+FOLFOX-HAIC shows promise in high-risk advanced HCCSeptember 19, 2022Hepatocellular Carcinoma
HCC: Averting post-TARE hepatic decompensation with careful patient selection September 19, 2022Hepatocellular Carcinoma
Postoperative adjuvant TACE efficacy in HCC depends on micronecrosis stateSeptember 19, 2022Hepatocellular Carcinoma
Unresectable HCC: Atezolizumab+bevacizumab more effective in patients with good liver functionSeptember 19, 2022Hepatocellular Carcinoma
Advanced HCC with macroscopic PVTT: Hepatectomy offers better survival than sorafenibSeptember 19, 2022Hepatocellular Carcinoma
Transradial vs transfemoral access for TACE improves patient satisfaction in HCCSeptember 19, 2022Hepatocellular Carcinoma
CP-A to CP-B progression after lenvatinib initiation in HCC should not halt therapySeptember 19, 2022Hepatocellular Carcinoma
Sintilimab plus IBI305: A promising treatment option for advanced HCCSeptember 19, 2022Hepatocellular Carcinoma
